NCT06486142View on ClinicalTrials.gov

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Afatinib/Dacomitinib

Second-generation EGFR-inhibitors

DRUG

Osimertinib

Third-generation EGFR-inhibitor

Trial Locations (1)

Unknown

RECRUITING

Skåne university hospital, Lund

All Listed Sponsors
collaborator

Swedish Lung Cancer Study Group

NETWORK

lead

Region Skane

OTHER